Aptorum Group (NASDAQ:APM) & Profound Medical (NASDAQ:PROF) Head-To-Head Comparison

Profound Medical (NASDAQ:PROF) and Aptorum Group (NASDAQ:APM) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, risk, earnings, analyst recommendations, dividends, institutional ownership and profitability.

Analyst Ratings

This is a breakdown of current ratings and target prices for Profound Medical and Aptorum Group, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Profound Medical	1	0	1	0	2.00
Aptorum Group	1	0	0	0	1.00

Profound Medical presently has a consensus price target of $12.00, suggesting a potential upside of 92.62%. Given Profound Medical’s stronger consensus rating and higher possible upside, analysts clearly believe Profound Medical is more favorable than Aptorum Group.

Profitability

This table compares Profound Medical and Aptorum Group’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Profound Medical	-275.16%	-86.18%	-70.55%
Aptorum Group	N/A	N/A	N/A

Insider & Institutional Ownership

47.9% of Profound Medical shares are held by institutional investors. Comparatively, 3.8% of Aptorum Group shares are held by institutional investors. 1.5% of Profound Medical shares are held by insiders. Comparatively, 64.0% of Aptorum Group shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Earnings & Valuation

This table compares Profound Medical and Aptorum Group”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Profound Medical	$10.68 million	21.17	-$27.82 million	($1.34)	-4.65
Aptorum Group	$430,000.00	12.58	-$4.27 million	N/A	N/A

Aptorum Group has lower revenue, but higher earnings than Profound Medical.

Risk and Volatility

Profound Medical has a beta of 0.6, meaning that its share price is 40% less volatile than the S&P 500. Comparatively, Aptorum Group has a beta of 0.11, meaning that its share price is 89% less volatile than the S&P 500.

Summary

Profound Medical beats Aptorum Group on 7 of the 12 factors compared between the two stocks.

About Profound Medical

Profound Medical Corp., together with its subsidiaries, operates as a commercial-stage medical device company that develops and markets incision-free therapeutic systems for the image guided ablation of diseased tissue in Canada, Germany, the United States, and Finland. Its lead product TULSA-PRO system combines magnetic resonance imaging(MRI), robotically-driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to provide precise, flexible, and durable ablation of a surgeon defined region of prostate and protect the urethra and rectum. The company also offers Sonalleve, which combines real-time MRI and thermometry for the treatment of uterine fibroids, adenomyotic tissue, palliative pain treatment of bone metastases, osteoid osteoma, and management of benign tumors. Profound Medical Corp. is headquartered in Mississauga, Canada.

About Aptorum Group

Aptorum Group Limited, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic products for the treatment of infectious diseases and cancer. The company operates in the Therapeutics and Non-Therapeutics segments. Its pipeline products include SACT- 1 for neuroblastoma and other cancer types; SACT-COV19 for the treatment of coronavirus disease; ALS-4 to treat bacterial infections caused by staphylococcus aureus, including MRSA; and ALS-1 to treat viral infections caused by influenza virus A. The company is also developing ALS-2/3 for the treatment of gram+ve bacterial infections; RPIDD, a pathogen molecular diagnostic; NativusWell DOI (NLS-2), a dietary supplement; NLS-1 for the treatment of endometriosis; DLS-1+2 to treat NSCLC with mutation; DLS-3, an autoimmune small molecule; and CLS-1 for the treatment of obesity. Its pipeline products enable the discovery of new therapeutics assets, such as systematic screening of existing approved drug molecules, and microbiome-based research platforms for treatment of metabolic diseases. The company also focuses on therapeutic and diagnostic projects in neurology, gastroenterology, metabolic disorders, women's health, and other disease areas. In addition, it operates a medical clinic. The company was formerly known as APTUS Holdings Limited and changed its name to Aptorum Group Limited in October 2017. Aptorum Group Limited was incorporated in 2010 and is headquartered in London, the United Kingdom. Aptorum Group Limited is a subsidiary of Jurchen Investment Corporation.